| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10314788 | OHEMO LIFE | Pharmaceutical compositions configured to deter dosage form splitting |
Aug, 2028
(4 years from now) | |
| US7955619 | OHEMO LIFE | Abuse resistant drugs, method of use and method of making |
Aug, 2028
(4 years from now) | |
Morphabond Er is owned by Ohemo Life.
Morphabond Er contains Morphine Sulfate.
Morphabond Er has a total of 2 drug patents out of which 0 drug patents have expired.
Morphabond Er was authorised for market use on 02 October, 2015.
Morphabond Er is available in tablet, extended release;oral dosage forms.
The generics of Morphabond Er are possible to be released after 12 August, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-189) | Oct 02, 2018 |
Drugs and Companies using MORPHINE SULFATE ingredient
Market Authorisation Date: 02 October, 2015
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
How can I launch a generic of MORPHABOND ER before it's drug patent expiration?
More Information on Dosage
MORPHABOND ER family patents
